Abstract
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
Author supplied keywords
Cite
CITATION STYLE
APA
Grant, L. M., & Orenstein, R. (2022). Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp. Journal of Investigative Medicine High Impact Case Reports, 10. https://doi.org/10.1177/23247096221123144
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free